The dental mirrors market is expected to grow from US$ 322. 31 million in 2022 to US$ 505. 44 million by 2028; it is expected to grow with a CAGR of 7. 8% from 2022 to 2028. The increasing prevalence of dental diseases, surging demand for dental cosmetic procedures, and a rising number of dentists and dental clinics are the major factors boosting the market.
New York, Sept. 27, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Dental Mirrors Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product Type, Material, Type, and End User” – https://www.reportlinker.com/p06321029/?utm_source=GNW
The incidence of dental and oral conditions, including tooth canal infection, dry mouth, tooth loss, cavities, and dental trauma, is rising worldwide. According to the WHO’s Global Burden of Disease 2019 study, around 3.5 billion people worldwide suffer from oral diseases, especially tooth caries. The increasing prevalence rate of dental problems, such as crooked teeth, spaces between teeth, overbites, and teeth overcrowding, has increased the need for dental procedures to treat such, which, in turn, drives the growth of the dental mirrors market. For instance, as per the Centers for Disease Control and Prevention (CDC), approximately 47.2% of the adults in the age group above 30 years have some periodontal disease in the US, and it increases with age, with around 70.1% of adults over the age of 65 years have periodontal disease in 2020.
Furthermore, the population in low- and middle-income countries (LMICs) has a comparatively higher prevalence of oral diseases, and it continues to increase with growing urbanization and lifestyle changes. According to a study by the University of Gondar, Ethiopia, the prevalence rate of oral diseases, especially in sub-Saharan Africa, was 40.98%, for Ethiopia, 52.4%; Sudan and Kenya have a prevalence rate of 50.3%, and Tanzania has a prevalence rate of 40.2% in 2020. This high prevalence is primarily caused due to inadequate exposure to fluoride in oral hygiene products or within water supply, availability of food with high sugar content, and poor access to oral health services in the community. The growing food and beverages with high sugar content and tobacco and alcohol consumption are contributing to oral health conditions and other non-communicable diseases.
Product Type Insights
Based on the product type, the dental mirrors market is segmented into one-sided mirrors, double-sided mirrors, LED dental mirrors, and smart dental mirrors.The one-sided mirrors segment is likely to hold the largest market share in 2022.
However, the smart dental mirror segment is anticipated to register the highest CAGR during the forecast period. The one-sided mirrors give a brighter and magnified image of the original object without inverting the image; thus, dentists can see a larger image of what is inside, making the doctor’s work much easier in viewing inner teeth and the mouth, thereby increasing adoption by dentists is driving the one-sided mirrors growth of the segment.
Material Insights
Based on material, the dental mirrors market is bifurcated into metal dental mirrors and plastic dental mirrors.The metal dental mirrors segment is likely to hold a larger market share in 2022.
Furthermore, the same segment is expected to record a faster CAGR from 2022 to 2028. Both aluminum and silver coating can offer unique benefits that improve the functionality of optical mirrors.
Furthermore, silver coatings benefit primary, secondary, and tertiary mirrors because of their high reflectance and lasting durability, which increases the adoption of metal dental mirrors and are major driving factors for the growth of the metal dental mirrors segment.
End user Insights
Based on end user, the dental mirrors market is segmented into dental clinics, hospitals, and others. by the end of 2022, the dental clinics segment is likely to hold the largest share in the market. Furthermore, the same segment is expected to register the highest CAGR from 2022 to 2028. The growth of the dental clinics segment is attributed to factors such as the increasing number of dental clinics globally, the surge in prevalence of dental disorders, and the increasing disposable income of people. The dental clinic provides all kinds of dental treatment facilities such as periodontics, orthodontics, dental mirrors, teeth whitening, preventive dentistry, and others.
The National Center for Biotechnology Information (NCBI); Centers for Disease Control and Prevention (CDC); World Health Organization (WHO); US Bureau of Economic Analysis, Australian Dental Association, Gerodontology Association, European Centre for Disease Prevention and Control, Oral Health Foundation, are among the primary and secondary sources referred to while preparing the report on the dental mirrors market.
Read the full report: https://www.reportlinker.com/p06321029/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
In the past two years, biotech companies Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) rose to fame thanks to their successful attempts to develop vaccines for COVID-19 and help us end the outbreak. The pandemic isn't over yet, but Moderna and Novavax have given up substantial chunks of their value in the past year. Where does that leave Moderna and Novavax?
The medicine, called Relyvrio, gives patients with the degenerative disease a new treatment option, but some FDA staff questioned its effectiveness.
A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.
Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Several biotech stocks have outperformed the struggling market this year. This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN). Let's consider why these three biotechs are solid buys for the next decade.
Biogen has spent much of the year shedding assets following the disastrous rollout of its first Alzheimer's disease drug. Will its new Alzheimer's drug stop that decline?
If so, it was probably for something like Berkshire Hathaway (NYSE: BRK.A), with an eye-popping price of $419,020 per share. Thankfully, there are much cheaper companies to buy, and some of them might even grow a bit faster than Warren Buffett's business. With its shares trading for around $13, having gained 139% in the past 12 months, Catalyst Pharmaceuticals (NASDAQ: CPRX) is a little-known biotech stock that's positioned to keep paying off for investors thanks to its progress in treating a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome (LEMS).
Wonder Pill quietly contained a drug used to treat erectile dysfunction, which could be deadly for some unknowing consumers, the FDA said.
Shares of Nano-X Imaging (NASDAQ: NNOX), commonly called Nanox, soared on Wednesday after it revealed it's taken the next step toward commercializing its flagship medical device. As of 12:20 p.m. ET, Nanox stock was up 21%. Nanox had its initial public offering (IPO) in 2020, promising to disrupt the X-ray industry with its digital-3D imaging machines that will be cheaper for doctors to use.
After a long road, Amylyx Pharmaceuticals won FDA approval for its ALS treatment late Thursday, leading AMLX stock to surge.
Vas Narasimhan, CEO of Novartis, talks about the Big Pharma company's new focus on the U.S. market—and why he believes investors are undervaluing its potential.
Dr. Anthony Fauci and his wife, Christine Grady, experienced millions in increased net worth as many Americans struggled during the pandemic, according to a watchdog group.
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
Biogen stock catapulted Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a test.
Both the flu vaccine and the COVID vaccine can be given simultaneously
Cambridge, Massachusetts-based biotech Biogen and Japanese drug maker Eisai reported on Wednesday morning that their experimental Alzheimer's disease treatment had met the main goal of a late-stage clinical trial. The candidate, Lecanemab, reduced the pace of cognitive decline in patients diagnosed with early-stage disease by 27% over 18 months compared to those treated with a placebo. This result could be a major accomplishment for researchers who have been trying for decades to find a way to treat Alzheimer's. The medicine, before Biogen and Eisai started trying to develop it, was licensed from Sweden's BioArctic.
Philecia La'Bounty felt a lump in her breast but was denied a mammogram due to her age and family history — months later, she found out she had breast cancer that had metastasized
The Inflation Reduction Act will send hundreds of billions towards efforts ranging from fighting climate change to reducing the deficit. But you wouldn't know about all that by listening to Democratic and Republican lawmakers in recent weeks.
